GLENMARK · NSE
Glenmark Pharmaceuticals Limited
₹2,648
+1.51% (+₹39.5)
Prev. close
₹2,608.5
Volume
5,40,171
Delivery %
48.8%
As of
20 Nov 2026
Price history
Analyst sentiment
Analysts lean bullish
2 analyst stances · last 90 days · one per analyst
Trackable
2 · 2 bull / 0 neutral / 0 bear
Long-Horizon
none in range
Commentary
none in range
Trackable = verdict-bearing calls · Long-Horizon = 1yr+ horizon, verdict pending · Commentary = context, not graded
Analyst opinions
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Bullish on Glenmark futures for the near term, recommending a buy in the ₹2,450-2,465 range with targets of ₹2,520 and ₹…” | Jay ThakkarICICI Securities | Glenmark Pharmaceuticals | MISS | |
| “Bullish on Glenmark Pharmaceuticals futures, recommending a buy in the ₹2,480-2,490 range with a stop loss below ₹2,440 …” | Jay ThakkarICICI Securities | Glenmark Pharmaceuticals | NOT TRIGGERED | |
| “Bullish on Glenmark Pharmaceuticals, recommending a buy at CMP Rs 2,515 with a target of Rs 2,701 and a stop loss of Rs …” | Nilesh JainCentrum Finverse Ltd. | Glenmark Pharmaceuticals | MISS | |
| “Bullish on Glenmark Pharma for intraday trading, recommending a buy at ₹2332 with a target of ₹2450 and a stop loss at ₹…” | Vaishali ParekhPrabhudas Lilladher | Glenmark Pharma | HIT | |
| “Bullish on Glenmark Pharmaceuticals, recommending a buy with a target price of ₹2,470 and a stop loss of ₹2,260. The sto…” | Chandan TapariaMotilal Oswal Financial Services Ltd | Glenmark Pharmaceuticals | HIT | |
| “CA Rudramurthy BV is bullish on Glenmark Pharma, recommending a buy based on a clear bottom formation and accumulation p…” | CA Rudramurthy BVVachana Investments | Glenmark Pharmaceuticals Ltd | MISS | |
| “Glenmark Pharmaceuticals is primed for a breakout, currently consolidating after a good recovery and sitting at the edge…” | Nagaraj ShettiHDFC Securities | Glenmark Pharmaceuticals Limited | HIT | |
| “Recommends buying Glenmark above ₹1995 with a stop loss at ₹1970 and a target of ₹2040 for an intraday trade. This pick …” | Raja VenkatramanNeoTrader | Glenmark Pharmaceuticals Ltd | MISS | |
| “Recommends buying Glenmark with a target of ₹2,140 and a stop loss at ₹1,930. The stock has shown a fresh 6-month consol…” | Sagar DoshiNuvama Professional Clients Group | Glenmark Pharmaceuticals Ltd | MISS | |
| “Conditionally bullish on Glenmark Pharma, recommending a buy once it crosses the resistance area of 1975 (currently at 1…” | Rahul SharmaJM Financial Services | Glenmark Pharmaceuticals Ltd | HIT | |
| “Suggests buying Glenmark Pharma for a target of ₹2,050–2,200 with a stop loss at ₹1,880. This bullish view follows a bre…” | Rahul SharmaJM Financial Services | Glenmark Pharmaceuticals Ltd | HIT | |
| “Bullish on Glenmark Pharmaceuticals for the next 1-2 weeks, with a target price of ₹2,100 and a stop loss at ₹1,870. The…” | Ajit MishraReligare Broking | Glenmark Pharmaceuticals | MISS | |
| “Bullish on Glenmark Pharmaceuticals Futures for the near term. The stock has formed a base after a sharp fall, with rece…” | Jay ThakkarICICI Securities | Glenmark Pharmaceuticals | NOT TRIGGERED | |
| “Bullish on Glenmark Pharmaceuticals with a target of ₹2300. The call implies a positive outlook on the stock's performan…” | Deven ChokseyIndependent | Glenmark Pharmaceuticals | HIT | |
| “Bullish on Glenmark Pharmaceuticals, which shows strong bullish momentum with daily RSI at 71.6, MACD at +32.6, and ADX …” | Ankush BajajTrade Brains Portal | Glenmark Pharmaceuticals Ltd | MISS | |
| “Recommends buying Glenmark Pharmaceuticals today, September 10, at ₹2,116.30, targeting ₹2,149 with a stop loss at ₹2,09…” | Ankush BajajIndependent | Glenmark Pharmaceuticals Ltd | MISS | |
| “Recommends buying Glenmark Pharmaceuticals at ₹2049, targeting ₹2200, with a stop loss at ₹1960.” | Vaishali ParekhPrabhudas Lilladher | Glenmark Pharmaceuticals | MISS | |
| “Bullish on Glenmark Pharmaceuticals for the short term (1-2 weeks), recommending a buy with a target price of ₹2,150 and…” | Ajit MishraReligare Broking | Glenmark Pharmaceuticals | MISS | |
| “Bullish on Glenmark Pharmaceuticals with a target of ₹2300. The call implies a positive outlook on the stock's performan…” | Deven ChokseyIndependent | Glenmark Pharmaceuticals | HIT | |
| “Bullish on Glenmark Pharmaceuticals Ltd., recommending a buy at ₹21333 with a stop loss at ₹2100 for a target price of ₹…” | Ganesh DongreAnand Rathi | Glenmark Pharmaceuticals Ltd. | MISS | |
| “Recommends buying Glenmark Pharmaceuticals between ₹2145-2150, setting a stop loss at ₹2100 and a target price of ₹2200.…” | Ganesh DongreAnand Rathi | Glenmark Pharmaceuticals Ltd | MISS | |
| “Bullish on Glenmark Pharmaceuticals Ltd for short-term traders, recommending a buy around ₹2143 with a target price of ₹…” | Ganesh DongreAnand Rathi | Glenmark Pharmaceuticals Ltd | MISS | |
| “Bullish on Glenmark Pharma, recommending a buy at ₹2,225.50 with a target of ₹2,280 and a stop loss at ₹2,194. The stock…” | Ankush BajajIndependent | Glenmark Pharmaceuticals Ltd | NOT TRIGGERED | |
| “Bearish on Glenmark Pharmaceuticals with a 'Sell' recommendation, targeting ₹1620. The call implies an expectation of pr…” | ICICI Securities AnalysisICICI Securities | Glenmark Pharmaceuticals | MISS | |
| “Reiterated a 'buy' rating on Glenmark Pharmaceuticals with a raised target price of ₹2,430, implying a 28% upside from t…” | Motilal Oswal AnalysisMotilal Oswal Financial Services | Glenmark Pharmaceuticals | MISS | |
| “Bullish on Glenmark Pharma, recommending a buy at ₹1904.00 with a target of ₹1975–₹1980 and a stop loss at ₹1855.00. The…” | Ankush BajajIndependent | Glenmark Pharmaceuticals Ltd | NOT TRIGGERED | |
| “Bullish on Glenmark Pharmaceuticals, recommending a buy around ₹1904 with a stop loss at ₹1837 for a target price of ₹20…” | Sumeet BagadiaChoice Equity Broking | Glenmark Pharmaceuticals Ltd | NOT TRIGGERED | |
| “Recommends buying Glenmark Pharma with a target of ₹1880 and a stop loss at ₹1800, suggesting a short-term bullish view.” | Kunal BothraIndependent | Glenmark Pharmaceuticals Ltd | PENDING | |
| “Bullish on Glenmark Pharma, which has made a fresh lifetime high, signaling strong bullish sentiment and price action. T…” | Ankush BajajIndependent | Glenmark Pharmaceuticals Ltd | PENDING | |
| “Recommends buying Glenmark Pharma, citing its outperformance within the pharma space, a continuation pattern breakout on…” | Rajesh BhosaleAngel One | Glenmark Pharmaceuticals Ltd | HIT | |
| “Glenmark Pharma has broken out of an 8-month consolidation and a downward trendline, signaling further upside potential.…” | Religare Broking AnalysisReligare Broking | Glenmark Pharmaceuticals Ltd | PENDING | |
| “Bullish on Glenmark Pharmaceuticals, recommending a buy at ₹1,584.80 with a target of ₹1,660-1,690 in 4-5 days. The call…” | Ankush BajajIndependent | Glenmark Pharmaceuticals Ltd | MISS | |
| “Bullish on Glenmark Pharmaceuticals (GLENMARK), recommending a buy around ₹1410 with a stop loss at ₹1370 for a target o…” | Ganesh DongreAnand Rathi | Glenmark Pharmaceuticals Ltd | PENDING | |
| “Maintains a 'Reduce' call on Glenmark Pharmaceuticals with a revised target price of ₹1,300, down from the current marke…” | ICICI Securities AnalysisICICI Securities | Glenmark Pharmaceuticals Ltd | MISS | |
| “Bullish on Glenmark Pharmaceuticals for the short term, recommending a buy with a target of ₹1,830 and a stop-loss at ₹1…” | Riyank AroraMehta Equities | Glenmark Pharmaceuticals | MISS | |
| “Maintains a 'Reduce' call on Glenmark Pharmaceuticals with a revised target price of ₹1,265 (from ₹1,345), based on 22x …” | ICICI Securities AnalysisICICI Securities | Glenmark Pharmaceuticals Ltd | MISS | |
| “Recommends buying Glenmark Pharmaceuticals with a target price of ₹1768. The call implies a bullish outlook on the stock…” | Deven Choksey Research AnalysisDeven Choksey Research | Glenmark Pharmaceuticals | PENDING | |
| “Bullish on Glenmark, recommending it as a 'buy-on-dip' candidate for positional views at 1380, with a stop loss at 1280 …” | Aditya AroraAdlytick | Glenmark Pharmaceuticals Limited | MISS | |
| “Bullish on Glenmark; recommends buying at ₹1734 with a target of ₹1855 and a stop loss at ₹1675. The stock gave an insid…” | Chandan TapariaMotilal Oswal Financial Services Ltd | Glenmark Pharmaceuticals Limited | MISS | |
| “Bullish on Glenmark Pharmaceuticals with a 'Buy' call and a target price of ₹1,894 apiece for October. The firm expects …” | Deven ChokseyDRChoksey FinServ Pvt. Ltd | Glenmark Pharmaceuticals Ltd | PENDING |
Market commentary · 6 · levels, conditionals, previews, macro & hedged views — context, not graded
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Bullish on Glenmark Pharma, expecting shares to test ₹2,600 to ₹2,800 in the short term, implying a 29% upside from curr…” | Anuj GuptaYa Wealth Global Research | Glenmark Pharmaceuticals Ltd | — | |
| “Bullish on Glenmark Pharma, noting the stock's positive technical structure despite Friday's sharp rally and its emergen…” | Nilesh JainCentrum Finverse Ltd. | Glenmark Pharmaceuticals Ltd | — | |
| “Reiterated a 'Buy' rating on Glenmark Pharma, seeing a 28% upside from Thursday’s closing price of ₹1,904, with a 12-mon…” | Motilal Oswal AnalysisMotilal Oswal Financial Services | Glenmark Pharmaceuticals Ltd | — | |
| “Bullish on Glenmark Pharmaceuticals Ltd, which has broken out above a Rounded Bottom formation near ₹1,830 on the weekly…” | Rajesh PalviyaAxis Securities | Glenmark Pharmaceuticals Ltd | — | |
| “Bullish on Glenmark Pharmaceuticals, which has decisively surpassed its 1555 resistance zone with huge volumes. Positive…” | Rajesh PalviyaAxis Securities | Glenmark Pharmaceuticals Ltd | — | |
| “Recommends buying Glenmark Pharma this week at ₹1790, targeting a new lifetime high of ₹1950 with a stop loss at ₹1720. …” | Motilal Oswal AnalysisMotilal Oswal Financial Services | Glenmark Pharmaceuticals Limited | — |
Fundamentals
About Glenmark Pharmaceuticals Limited
Glenmark Pharmaceuticals Limited, together with its subsidiaries, research, develops, manufactures, and sells generics, specialty medicines, and over the counter (OTC) pharmaceutical products in India, North America, Europe, and internationally. The company provides various products in the therapeutic areas of dermatology, respiratory, oncology, cardiology, diabetes, gynecology, gastroenterology, and anti-infective in the dosage forms of complex injectables and biologics, oral solids, liquids, topical products, and respiratory-metered dose inhaler, dry powder inhaler, and nasal sprays. Its product pipeline includes ISB 2001, a CD38 x BCMA x CD3 trispecific T cell engager, which is in Phase 1 clinical trial for indication of multiple myeloma; ISB 2301, a Multispecific Immune Cell Activator that is in preclinical trial for solid tumors; ISB 2302, a bispecific immune modulator with an indication for hematologic and solid tumors; and ISB 2501, a trispecific T-cell engager indicated for solid tumors. The company's pipeline also comprises ISB 880, an IL-1RAP antagonist monoclonal antibody, which is in Phase 2 clinical trial for the treatment of hidradenitis suppurativa; and telazorlimab and ISB 830-X8, a OX40 antagonist mAb for the treatment of atopic dermatitis. In addition, the company offers Ryaltris, fixed-dose nasal spray for the treatment of allergic rhinitis. The company was incorporated in 1977 and is based in Mumbai, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Glenn Mario Saldanha
Headquarters
Mumbai
Employees
16,946
Website
glenmarkpharma.comExchange
View on NSE ↗Key stats
Market cap
₹70,350.14 Cr
P/E ratio (TTM)
39.6
Dividend yield
0.21%
EPS (TTM)
₹63.00
Beta (1Y · daily vs NIFTY 50)
0.91
Beta (5Y · monthly vs NIFTY 50)
0.90
Shares float
15.02 Cr
EPS · quarter ended Jun 2026
₹17.11
Financial Performance
01 · Financials
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based
05 · Capital Structure & Asset Utilization
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
07 · Debt Level & Coverage
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹10,943.93 Cr | ₹12,304.90 Cr | ₹11,431.94 Cr | ₹11,813.10 Cr | ₹13,321.74 Cr | ₹16,982.51 Cr | |
EBITDA | ₹2,179.14 Cr | ₹2,226.06 Cr | ₹1,200.15 Cr | ₹1,183.27 Cr | ₹2,092.28 Cr | ₹2,766.95 Cr |
| ₹970.09 Cr | ₹941.71 Cr | ₹297.25 Cr | ₹-1,501.67 Cr | ₹1,047.10 Cr | ₹1,361.85 Cr | |
Diluted EPS | ₹34.38 | ₹33.37 | ₹10.53 | ₹-53.22 | ₹37.1 | ₹48.24 |
Net income for Mar 2021 could not be checked against the company's own annual report: this page shows ₹970.09 Cr while the annual report gives ₹1,649.45 Cr (70.0% apart).
EBITDA for Mar 2021 could not be checked against the company's own annual report: this page shows ₹2,179.14 Cr while the annual report gives ₹2,360.47 Cr (8.3% apart).
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹15,575.00 Cr | ₹17,052.00 Cr | ₹19,371.00 Cr | ₹14,358.00 Cr | ₹15,991.00 Cr | ₹19,907.00 Cr | |
| — | ₹3,962.02 Cr | ₹4,607.88 Cr | ₹1,230.93 Cr | ₹2,472.67 Cr | ₹593.53 Cr | |
Stockholders' equity | ₹7,064.00 Cr | ₹9,086.00 Cr | ₹9,474.00 Cr | ₹7,848.00 Cr | ₹8,849.00 Cr | ₹10,512.00 Cr |
Current assets, Cash & equivalents, Non-current assets, Others, Total debt, Long-term debt, Current (short-term) debt have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹1,131.00 Cr | ₹1,109.00 Cr | ₹625.00 Cr | ₹-265.00 Cr | ₹-828.00 Cr | ₹3,445.00 Cr | |
Investing cash flow | ₹-675.24 Cr | ₹-333.28 Cr | ₹-528.49 Cr | ₹4,560.89 Cr | ₹2.09 Cr | ₹-1,283.23 Cr |
| ₹-442.00 Cr | ₹-520.00 Cr | ₹-77.00 Cr | ₹-3,906.00 Cr | ₹787.00 Cr | ₹-2,709.00 Cr | |
Capital expenditure | ₹-775.00 Cr | ₹-790.00 Cr | ₹-608.00 Cr | ₹-898.00 Cr | ₹-751.00 Cr | ₹-1,358.00 Cr |
End cash position | ₹1,138.10 Cr | ₹1,410.53 Cr | ₹1,443.03 Cr | ₹1,658.27 Cr | ₹1,675.71 Cr | ₹1,174.71 Cr |
Debt issued, Debt repaid have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 20 | Sep 21–Dec 23(10Q) | Mar 24 | Jun 24–Jun 26(9Q) |
|---|---|---|---|---|
| Promoter | 46.63% | 46.65% | 46.64% | 46.65% |
| Public | 53.37% | 53.35% | 53.36% | 53.35% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.25 L Cr | ₹1,769.9 | 38.8 | 5.09 | 13.7% | 0.06 | +11.9% | +3.7% |
| Divi's Laboratories Limited | ₹2.66 L Cr | ₹10,037.5 | 90.8 | 15.85 | 15.3% | 0.00 | +12.3% | +47.5% |
| Torrent Pharmaceuticals Limited | ₹1.79 L Cr | ₹4,738.5 | 79.4 | 21.31 | 25.8% | 1.79 | +21.5% | +32.5% |
| Laurus Labs Limited | ₹1.27 L Cr | ₹2,348 | 94.8 | 23.94 | 16.8% | 0.48 | +22.0% | +146.2% |
| Apollo Hospitals Enterprise Limited | ₹1.23 L Cr | ₹8,599.5 | 58.8 | 12.95 | 20.5% | 0.90 | +15.7% | +10.1% |
| Zydus Lifesciences Limited | ₹1.19 L Cr | ₹1,188.1 | 26.7 | 4.40 | 18.6% | 0.46 | +18.4% | +22.3% |
| Lenskart Solutions Limited | ₹1.16 L Cr | ₹689.7 | 181.4 | 13.30 | 5.6% | 0.35 | +35.4% | — |
| Dr. Reddy's Laboratories Limited | ₹1.14 L Cr | ₹1,374 | 40.6 | 3.02 | 11.4% | 0.21 | +3.2% | +14.5% |
| Cipla Limited | ₹1.13 L Cr | ₹1,402 | 38.9 | 3.27 | 11.3% | 0.02 | +2.1% | -6.7% |
| Mankind Pharma Limited | ₹1.03 L Cr | ₹2,475 | 45.9 | 6.31 | 11.7% | 0.39 | +17.0% | +3.1% |
| Aurobindo Pharma Limited | ₹98,101.93 Cr | ₹1,705 | 26.6 | 2.59 | 9.2% | 0.21 | +6.4% | +48.4% |
| Glenmark Pharmaceuticals Limited | ₹70,350.14 Cr | ₹2,504.7 | 39.6 | 6.69 | 13.0% | 0.06 | +27.1% | +35.7% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.